EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study

Jesús Peña-Martín, María Belén García-Ortega, José Luis Palacios-Ferrer, Caridad Díaz, María Ángel García, Houria Boulaiz, Javier Valdivia, José Miguel Jurado, Francisco M Almazan-Fernandez, Salvador Arias Santiago, Francisca Vicente, Coral Del Val und 2 weitere

British Journal of Dermatology · 2024

DOI: 10.1093/bjd/ljae013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2024. Verfasst von Jesús Peña-Martín und 13 weiteren Autor:innen. Beteiligte Einrichtung: Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM). Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III, Junta de Andalucía.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Malignant melanoma (MM) is a highly aggressive form of skin cancer whose incidence continues to rise worldwide. If diagnosed at an early stage, it has an excellent prognosis, but mortality increases significantly at advanced stages after distant spread. Unfortunately, early detection of aggressive melanoma remains a challenge.

Objectives

To identify novel blood-circulating biomarkers that may be useful in the diagnosis of MM to guide patient counselling and appropriate disease management.

Methods

In this study, 105 serum samples from 26 healthy patients and 79 with MM were analysed using an untargeted approach by liquid chromatography coupled to high-resolution mass spectrometry (LC-HRMS) to compare the metabolomic profiles of both conditions. Resulting data were subjected to both univariate and multivariate statistical analysis to select robust biomarkers. The classification model obtained from this analysis was further validated with an independent cohort of 12 patients with stage I MM.

Results

We successfully identified several lipidic metabolites differentially expressed in patients with stage I MM vs. healthy controls. Three of these metabolites were used to develop a classification model, which exhibited exceptional precision (0.92) and accuracy (0.94) when validated on an independent sample.

Conclusions

These results demonstrate that metabolomics using LC-HRMS is a powerful tool to identify and quantify metabolites in bodily fluids that could serve as potential early diagnostic markers for MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansPilot ProjectsEarly Detection of CancerMetabolomicsBiomarkersLiquid Chromatography-Mass Spectrometry

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Biopathology and Regenerative Medicine Institute (IBIMER), Centre for Biomedical Research (CIBM).
  • Department of Human Anatomy and Embryology, Faculty of Medicine.
  • Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
  • Excellence Research Unit "Modeling Nature" (MNat).
  • Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía. Parque Tecnológico Ciencias de la Salud, Granada, Spain.
  • Department of Biochemistry 3 and Immunology, Faculty of Medicine.

ORCID-Profile: Juan Antonio Marchal

Förderung

  • Ministerio de Ciencia e Innovación
  • Instituto de Salud Carlos III
  • Junta de Andalucía

Zitieren

APA

Peña-Martín, J., Belén García-Ortega, M., Palacios-Ferrer, J. L., Díaz, C., Ángel García, M., Boulaiz, H., Valdivia, J., Jurado, J. M., Almazan-Fernandez, F. M., Arias Santiago, S., Vicente, F., Del Val, C., Pérez Del Palacio, J., & Marchal, J. A. (2024). Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae013

Vancouver

Peña-Martín J, Belén García-Ortega M, Palacios-Ferrer JL, Díaz C, Ángel García M, Boulaiz H, et al. Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study. British Journal of Dermatology. 2024. doi:10.1093/bjd/ljae013

BibTeX
@article{PeaMartn2024,
  author = {Peña-Martín, Jesús and Belén García-Ortega, María and Palacios-Ferrer, José Luis and Díaz, Caridad and Ángel García, María and Boulaiz, Houria and Valdivia, Javier and Jurado, José Miguel and Almazan-Fernandez, Francisco M and Arias Santiago, Salvador and Vicente, Francisca and Del Val, Coral and Pérez Del Palacio, José and Marchal, Juan Antonio},
  title = {Identification of novel biomarkers in the early diagnosis of malignant melanoma by untargeted liquid chromatography coupled to high-resolution mass spectrometry-based metabolomics: a pilot study},
  journal = {British Journal of Dermatology},
  year = {2024},
  doi = {10.1093/bjd/ljae013}
}
Kostenlos starten →